Shiratronics completed enrollment in its study of neuromodulation for chronic migraine. The company develops a fully implantable system targeting the nerves involved in migraine, placing it among a small set of device makers pursuing implant-based treatment for a condition long managed pharmacologically. Completed enrollment moves the study toward the data readout that will define the therapy's clinical profile.